Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo)
DOI: 10.1055/s-0043-1771483
Artigo de Atualização | Update Article

Update on Conventional Osteosarcoma

Article in several languages: português | English
Luiz Eduardo Moreira Teixeira 
1   Departamento do Aparelho Locomotor da Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
,
Alex Guedes 
2   Grupo de Oncologia Ortopédica do Hospital Santa Izabel, Santa Casa de Misericórdia da Bahia, Salvador BA, Brasil
,
Suely Akiko Nakagawa 
3   Centro de Sarcomas e Tumores Ósseos, AC Camargo Cancer Center, São Paulo, SP, Brasil
,
Karine Corrêa Fonseca 
4   Grupo de Oncologia Pediátrico, Hospital das Clínicas, Belo Horizonte, MG, Brasil
,
Eduardo Ribeiro Lima 
4   Grupo de Oncologia Pediátrico, Hospital das Clínicas, Belo Horizonte, MG, Brasil
› Author Affiliations Financial Support This study received no specific funding from public, commercial, or not-for-profit sources.
› Further Information
   Permissions and Reprints

Abstract

Conventional osteosarcoma is a high-grade malignant tumor characterized by the production of osteoid matrix by malignant osteoblasts. It typically affects the long bones of children and adolescents. Treatment includes systemic chemotherapy and a local surgical approach with wide resection. Recent advances in oncology concepts, imaging, surgical planning, and cancer treatment protocols allow for improved survival and a higher limb preservation rate. This paper addresses the current status regarding the incidence, pathology, treatment, and prognosis of conventional high-grade osteosarcoma.

Keywords

sarcoma - osteosarcoma - neoplasms


Publication History

Received: 26 July 2022

Accepted: 27 March 2023

Article published online:
29 January 2024

© 2024. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Flanagan AM, Blay JY, Bovée JVMG. et al. Bone tumours: Introduction. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 340-444
    Google Scholar
  • 2 Baumhoer D, Böhling TO, Cates JMM. et al. Osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 403-409
    Google Scholar
  • 3 Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer 2022; 128 (11) 2107-2118
    Google Scholar
  • 4 Mansur SF, Barbosa CSP, Miranda D. et al. Sarcoma osteogênico - Estudo retrospectivo epidemiológico de 184 casos diagnosticados em Belo Horizonte, Minas Gerais. Rev Bras Ortop 1996; 31 (12) 995-1000
    Google Scholar
  • 5 Castro HC, Ribeiro KCB, Bruniera P. Osteossarcoma: Experiência do Serviço de Oncologia Pediátrica da Santa Casa de Misericórdia de São Paulo. Rev Bras Ortop 2008; 43 (04) 108-115
    Google Scholar
  • 6 Jadão FRS, Lima LS, Lopes JAS, Ribeiro MB. Avaliação dos fatores prognósticos e sobrevida de pacientes com Osteossarcoma atendidos em um Hospital Filantrópico de Teresina (PI), Brasil. Rev Bras Ortop 2013; 48 (01) 87-91
    Google Scholar
  • 7 Presti PF, Macedo CRD, Caran EM, Rodrigues AHD, Petrilli AS. Estudo epidemiológico de câncer na adolescência em centro de referência. Rev Paul Pediatr 2012; 30 (02) 210-216
    Google Scholar
  • 8 Yoshida A, Bredella MA, Gambarotti M, Sumathi VP. Low-grade central osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 400-402
    Google Scholar
  • 9 Guedes A, Oliveira MBDR, Costa FM, de Melo AS. Updating on bone and soft tissue sarcomas staging. Rev Bras Ortop 2021; 56 (04) 411-418
    Google Scholar
  • 10 Guedes A, Oliveira MBR, Melo AS, Carmo CCM. Update in imaging evaluation of bone and soft tissue sarcomas. [Published online: 2021-11-11] Rev Bras Ortop. Available from: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0041-1736569
    Google Scholar
  • 11 Wang J, Nord KH, O'Donnel PG, Yoshida A. Parosteal osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 410-413
    Google Scholar
  • 12 Binitie O, Morris CD. Conventional Osteoblastic Osteosarcoma. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthoopaedic Surgeons; 2021: 169-180
    Google Scholar
  • 13 Brookes MJ, Chan CD, Baljer B. et al. Surgical Advances in Osteosarcoma. Cancers (Basel) 2021; 13 (03) 388
    Google Scholar
  • 14 Ferguson PC, McLaughlin CE, Griffin AM, Bell RS, Deheshi BM, Wunder JS. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma. J Surg Oncol 2010; 102 (02) 120-124
    Google Scholar
  • 15 He F, Zhang W, Shen Y. et al. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg 2016; 36 ( Pt A ): 283-292
    Google Scholar
  • 16 Lawrenz JM, Mesko NW. General Principles of Wide Resection of Bone Tumors. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthopaedic Surgeons; Wolters Kluwer; 2021: 407-422
    Google Scholar
  • 17 Loh AHP, Wu H, Bahrami A. et al. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. Pediatr Blood Cancer 2015; 62 (02) 246-251
    Google Scholar
  • 18 Malawer MM, Wittig JC, Bickels J, Wiesel SW. Operative Techniques in Orthopaedic Surgical Oncology. 2nd ed. Philadelphia: Wolters Kluwer; 2016
    Google Scholar
  • 19 Ayerza MA, Farfalli GL, Aponte-Tinao L, Muscolo DL. Does increased rate of limb-sparing surgery affect survival in osteosarcoma?. Clin Orthop Relat Res 2010; 468 (11) 2854-2859
    Google Scholar
  • 20 Aponte-Tinao LA, Ayerza MA, Albergo JI, Farfalli GL. Do Massive Allograft Reconstructions for Tumors of the Femur and Tibia Survive 10 or More Years after Implantation?. Clin Orthop Relat Res 2020; 478 (03) 517-524
    Google Scholar
  • 21 Hamed Kassem Abdelaal A, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Tsuchiya H. Epiphyseal Sparing and Reconstruction by Frozen Bone Autograft after Malignant Bone Tumor Resection in Children. Sarcoma 2015; 2015: 892141
    Google Scholar
  • 22 Gross SW. The Classic: sarcoma of the long bones: based upon a study of one hundred and sixty-five cases. 1879. Clin Orthop Relat Res 2005; 438 (438) 9-14
    Google Scholar
  • 23 Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res 1982; (167) 250-254
    Google Scholar
  • 24 Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 1978; 53 (11) 695-700
    Google Scholar
  • 25 Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5 (01) 21-26
    Google Scholar
  • 26 Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37 (01) 1-11
    Google Scholar
  • 27 Bielack SS, Smeland S, Whelan JS. et al; EURAMOS-1 investigators. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. [published correction appears in J Clin Oncol 2016;34(33):4059] J Clin Oncol 2015; 33 (20) 2279-2287
    Google Scholar
  • 28 Ward WG, Mikaelian K, Dorey F. et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994; 12 (09) 1849-1858
    Google Scholar
  • 29 Akazawa R, Umeda K, Saida S. et al. Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. Jpn J Clin Oncol 2020; 50 (08) 948-952
    Google Scholar
  • 30 Senerchia AA, Macedo CR, Ferman S. et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment. Cancer 2017; 123 (06) 1003-1010
    Google Scholar
  • 31 Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. [published correction appears in J Clin Oncol 2001;19(9):2583] J Clin Oncol 2001; 19 (06) 1839-1847
    Google Scholar
  • 32 Kiany S, Gordon N. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. Methods Mol Biol 2016; 1441: 285-295
    Google Scholar
  • 33 Gordon N, Felix K, Daw NC. Aerosolized Chemotherapy for Osteosarcoma. Adv Exp Med Biol 2020; 1257: 67-73
    Google Scholar
  • 34 Chen Y, Liu R, Wang W. et al. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res 2021; 169: 105684
    Google Scholar
  • 35 Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021; 500: 1-10
    Google Scholar
  • 36 Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer 2016; 63 (10) 1780-1785
    Google Scholar
  • 37 Wang Y, Yu W, Zhu J. et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 2019; 38 (01) 168
    Google Scholar